Fortress Biotech Inc Stock Price, News & Analysis

Journey Medical Corporation (NASDAQ:DERM) reported Q2 2025 financial results with total revenues of $15.0 million, including $2.8 million from Emrosi™ in its first full quarter of sales. The company achieved a 67% gross margin, up from 61% in the prior year quarter, despite reporting a net loss of $3.8 million or $(0.16) per share.

Key highlights include Emrosi's expanded payer access covering over 100 million commercial lives in the U.S., up from 54 million in May 2025. The company joined the Russell 2000® and Russell 3000® Indexes in June 2025. Journey Medical maintained its cash position at $20.3 million as of June 30, 2025, and appointed Ramsey Alloush as Chief Operating Officer.

Journey Medical Corporation (NASDAQ:DERM) announced that its management team will ring the Nasdaq MarketSite closing bell on August 11, 2025, celebrating its 4-year anniversary as a public company and the commercial launch of Emrosi™, their new rosacea treatment.

CEO Claude Maraoui highlighted the company's consistent execution of its commercial strategy, led by their experienced management and specialized dermatology sales force. The company expects positive EBITDA later in 2025, citing strong initial revenue from Emrosi, improving margins, and a solid cash position.

Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on FDA-approved dermatological treatments, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be available on Journey Medical's website for approximately 30 days following the call.

Journey Medical Corporation (NASDAQ:DERM) announced significant expansion in commercial payer coverage for Emrosi™, its FDA-approved treatment for inflammatory rosacea lesions in adults. The coverage has increased to 65% of commercial lives (187 million) in the United States, up substantially from 29% in May 2025.

The expanded coverage is attributed to Journey Medical's targeted contracting strategy, increasing prescription demand, and strong clinical data showing Emrosi's superior efficacy over current standard treatments. The medication is available through specialty pharmacy chains, with the company positioning it to become the standard of care for rosacea treatment.

Journey Medical Corporation (Nasdaq: DERM) has announced its inclusion in both the Russell 2000® Index and Russell 3000® Index, effective after market close on June 27, 2025. This milestone is expected to enhance the company's visibility among investors and institutions.

The company's CEO highlighted the successful launch of Emrosi™, their FDA-approved treatment for inflammatory lesions of rosacea in adults. The medication contains 40 mg Minocycline Hydrochloride in a modified-release formulation. Management expressed optimism about 2025 being a transformational year, focusing on expanding access and growing prescription volume for Emrosi™.

Journey Medical Corporation announced new data analysis from Phase 3 trials of Emrosi (DFD-29) for treating moderate-to-severe papulopustular rosacea will be presented at SDPA 2025. The analysis showed Emrosi's efficacy is independent of patient body weight, based on two trials (MVOR-1 and MVOR-2) with 653 total participants. The drug demonstrated superior efficacy compared to both placebo and doxycycline, with success rates up to 75.5% in IGA treatment outcomes. As the lowest FDA-approved oral minocycline dose that doesn't require weight-based adjustments, Emrosi showed significant improvements in inflammatory lesion counts across all weight categories while maintaining a favorable safety profile.

Journey Medical Corporation announced that its FDA-approved rosacea treatment Emrosi was featured on Lifetime TV's 'The Balancing Act'. The segment, which premiered on June 9, 2025, and will be rebroadcast on June 19, showcases Emrosi, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory rosacea lesions in adults. The feature included expert insights from Dr. Saurabh Lodha of Pura Dermatology, highlighting Emrosi's unique formulation as the lowest-dose oral minocycline available. The treatment, FDA-approved in November 2024, is available by prescription at specialty pharmacies and represents what the company believes could be a paradigm shift in rosacea treatment.

Fortress Biotech (NASDAQ: FBIO) has completed the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction, which closed on May 30, 2025, will provide Fortress with approximately $28 million in immediate proceeds, plus potential additional benefits including a contingent value right (CVR) of up to $4.8 million and a 2.5% royalty on future net sales of UNLOXCYT. The deal values Checkpoint shares at $4.10 per share in cash, with stockholders eligible for an additional $0.70 per share through the CVR if UNLOXCYT receives approval in key European markets. UNLOXCYT, approved by the FDA in December 2024, is the first FDA-approved PD-L1 blocking antibody for advanced cutaneous squamous cell carcinoma. Fortress is now focusing on other initiatives, including their subsidiary Cyprium Therapeutics' CUTX-101 with a PDUFA date of September 30, 2025.

Fortress Biotech (FBIO) reported Q1 2025 financial results and corporate highlights. Key developments include: Emrosi™ commercial launch for rosacea treatment, pending acquisition of subsidiary Checkpoint Therapeutics by Sun Pharma (~$28M expected at closing), and FDA's acceptance of CUTX-101's New Drug Application for priority review with PDUFA date of September 30, 2025. Q1 financials show consolidated cash of $91.3M (up from $57.3M in Q4 2024), net product revenue of $13.1M, and net loss of $(12.7M) or $(0.48) per share. R&D expenses decreased to $3.9M from $24.8M year-over-year, while SG&A costs increased to $25.7M from $17.9M. The company's pipeline includes multiple late-stage programs and newly approved products, positioning it for continued growth and potential monetization opportunities.